This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Arthroaspis
ARTHROASPIS
Efficacy of undenatured collagen in knee osteoarthritis: review of the literature with limited meta-analysis
Prasoon Kumar et al.
Abstract: Background: Early knee osteoarthritis (OA) treatment is multimodal, with physical therapy and pharma co-therapy commonly used. Although popular, oral supplements like glucosamine and diacerein have not been reported to have high efficacy. Undenatured collagen type II (UC-II) has been introduced for therapy in early OA; it helps in cartilage repair and preservation. The present review was done to ascertain its efficacy in pain relief and knee function. Materials and methods: A systematic literature search was performed on MEDLINE (PubMed), Embase, Scopus, and Cochrane Library for published literature; studies comparing the outcome of UC-II supplementation with placebo/control in adult humans with early knee OA were included. The outcomes evaluated were VAS Score, quality of life – Western Ontario and McMaster Universities (WOMAC-score), Knee function, Knee range of motion, and any complications during the course of treatment. Results: A total of 293 results were obtained after a primary search; 8 randomized control trials (RCT) were finally included. A total of 243 patients received UC-II supplementation (91 men and 152 women). The overall mean age range for the intervention group was 53.5±0.99 to 68.7±5.3 years across all included studies, and the mean follow-up duration was 3 to 6 months. Outcome measures like WOMAC and VAS scores showed better outcomes with UC-II in comparison to placebo. Walking measurements improved significantly from the baseline, reflected in improved timed up-and-go and 6-minute walk tests (6MWT). The overall complications were similar to other supplements. Conclusion: With limited literature, UC-II has shown promise as a potent supplement in early knee OA with good pain relief and improved function. However, further large-scale studies are needed to substantiate these findings.
Am J Transl Res 2023;15(9):5545-5555 www.ajtr.org /ISSN:1943-8141/AJTR0151003
Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee – A randomized double- blind placebo-controlled trial
N. Kimmatkar et al.
Summary
Osteoarthritis is a common, chronic, progressive, skeletal, degenerative disorder, which commonly affects the knee joint. Boswellia serrata tree is commonly found in India. The therapeutic value of its gum (guggulu) has been known. It posses good anti-inflammatory, anti-arthritic and analgesic activity.
A randomized double-blind placebo-controlled crossover study was conducted to assess the efficacy, safety and tolerability of Boswellia serrata Extract (BSE) in 30 patients of osteoarthritis of knee, 15 each receiving active drug or placebo for eight weeks. After the first intervention,
washout was given and then the groups were crossed over to receive the opposite intervention
for eight weeks. All patients receiving drug treatment reported decrease in knee pain, increased
knee flexion and increased walking distance. The frequency of swelling in the knee joint was decreased. Radiologically there was no change. The observed differences between drug treated
and placebo being statistically significant, are clinically relevant. BSE was well tolerated by the
subjects except for minor gastrointestinal ADRs. BSE is recommended in the patients of osteoarthritis of the knee with possible therapeutic use in other arthritis.
Phytomedicine. 2003 Jan;10(1):3-7. doi: 10.1078/094471103321648593. PMID: 12622457.
Potential of Astaxanthin in the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial
Tabassum et al.
Abstract
Background: Osteoarthritis (OA) is a major disabling disorder of the elderly population worldwide. Pharmacotherapy focuses on symptomatic relief through nonsteroidal anti-inflammatory drugs (NSAIDs) or intra articular steroids, which are associated with significant adverse effects. Astaxanthin, a marine carotenoid, is a strong antioxidant with anti- inflammatory properties which may be a safe and effective alternative treatment.
Objectives: The purpose of the research was to look into how a commercially available astaxanthin supplement affected knee pain, stiffness, physical function and inflammatory markers in persons with moderate to severe knee osteoarthritis.
Methods: Adults with knee pain (n = 71, >40 years old), radiologically diagnosed with moderate to severe knee OA, participated in the 8-weeks double-blind, randomized, placebo-controlled trial. Participants consumed either 12 mg astaxanthin capsule each day or placebo identical to astaxanthin capsule. Knee outcomes were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) visual analog scale (normalized to scores of 0–100), serum hsCRP and IL-6 were measured. Outcomes were assessed at baseline, and at the end of 8th week.
Results: Knee pain and physical function score improved in both groups with greater improvements for astaxanthin (p<0.05) than for placebo (p>0.05) group. Total WOMAC score improved significantly in the astaxanthin (177.36 ± 12.6 to 166.95 ± 12.96) group than for placebo group (177.24 ± 12.45 to 175.09 ± 12.21). Serum hsCRP and IL-6 also reduced significantly in the astaxanthin group.
Conclusions: Astaxanthin consumption resulted in modest subjective improvements in knee pain, stiffness, and physical function in adults with moderate to severe knee OA with improvements in inflammatory markers.
Tabassum M, et al., J Ortho Sports Med 2025 DOI:10.26502/josm.511500177